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Original Article
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Background: To determine the efficacy of thrombolytics for the management of complex pleural fluid
collections.
Methods: We reviewed patients that received alteplase for persistent loculated pleural fluid collections
after simple tube drainage between July 01, 2007 and November 01, 2012. Our alteplase protocol is 6 mg of
alteplase in 50 mL of normal saline injected into the pleural chest tube. The chest tube is clamped for four
hours and then opened. Normally this is repeated daily for 2 to 3 days (d).
Results: One hundred and three [103] patients were identified with 110 interventions. Sixty-eight (66%)
of the patients were male, with ages ranging from 20–91 years (y), mean 57.2 y. Twenty (18.2%) patients
were trauma patients, 60 (55%) had hypertension and 32 (35%) were smokers. Most patients had one of the
following diagnoses: 79.6% (82/110) loculated pleural fluid collection as a result of an empyema or 20.4%
(21/110) retained hemothorax. The mean time from diagnosis to alteplase treatment for a hemothorax was
12.8 days (range, 1–32 days) and 16.2 days (range, 4–48 days) for an empyema. The mean duration of therapy
was 2.2±1.4 days (1–11 days). The time from alteplase to chest tube removal was 4.5 days (1–21 days). Eleven
of 103 (10.7%) patients required surgery including 3 video assisted decortications. The others had adequate
radiographic resolution. Seventeen patients (16.5%) died, in the hospital of: sepsis, respiratory failure, aortic
injury, and cardiac arrest.
Conclusions: Alteplase therapy is an effective alternative to surgery in most complex pleural fluid
collections.
Keywords: Empyema; infection; inflammation-systemic; lung; trauma
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Introduction

with antibiotics, drainage of the pleural fluid, and either

Pneumonia accounts for 1.3 million hospitalizations
annually, and of those admissions, 36 to 66 percent (%)
have pleural effusions (1). Patients are typically treated

intrapleural administration of fibrinolytic agents or
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operative drainage (2). Fibrinolytic agents are intended to
break up loculations in the infected pleural space and allow
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re-expansion of the lung (1,2). Mortality increases from 7%
to 33% as effusions evolve, leading to progressive sepsis
and shock (1). We report the use of alteplase in the pleural
space to decrease hospital stay, surgical interventions, and
complications. The objective of the study is to determine
the efficacy of thrombolytics for the management of
complex pleural fluid collections.
Methods
An institutional review board (IRB) approved retrospective
chart review was performed of all consecutive patients
treated at a single institution from July 01, 2007 to
November 01, 2012. The IRB ID number was 5130004.
The study was retrospective review and a waiver of
informed consent was approved by the IRB.
We examined all patients treated with alteplase for
loculated pleural fluid collections. Baseline patient
demographics, co-morbidities, smoking history, antibiotic
use, alteplase dose, number of days utilizing alteplase
therapy, and chest tube output after instillation were
recorded. All pleural fluid collections were class 5 or greater
as described by Light (3); although, not all effusions were
related to infection. Treatment endpoints were: (I) days to
resolution of pleural fluid collection; (II) time to surgery;
and (III) mortality.
The protocol is: 6 mg of alteplase in 50 mL of normal
saline instilled via a pleural chest tube. The chest tube is
clamped for 4 hours (dwell time); then, unclamped and
allowed to drain. One dose was given per 24 hour period,
for a total of three doses. Patients were evaluated with plain
chest radiographs (CXR) and chest computed tomography
(CT) prior to alteplase therapy and a CXR was performed
daily prior to repeat additional instillations. Patients who
showed complete clearance on the CXR after any dose
were considered to be adequately treated and additional
doses of alteplase were not given. Patients with a persistent
opacification on CXR after the third dose had been drained,
underwent a CT scan of the chest. Success of treatment
was determined by resolution or near resolution of the fluid
collection(s) on CT chest imaging. Patients with persistent
loculated effusions were considered to have failed medical
treatment and underwent decortication. Persistent loculated
effusions were determined based on the surgeons’ analysis
and read of the CT chest imaging. If the effusion was
equal to the size of the image prior to administration of
the effusion, it was considered unresolved and surgery was
indicated. If the effusion was significantly large, though,
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decreased in size from the initial effusion, it was considered
unresolved and surgery was indicated. Surgery was not
indicated if the effusion was significantly resolved, based
on the surgeon read of the imaging. The chest tube used
ranged from 8.5, 28 and 32 F chest tubes depending on
surgeon preference and size of the pleural effusion.
Statistical analysis was performed utilizing SAS software
to determine factors associated with failure of alteplase
therapy. Patient factors such as co-morbidities, history of
recent trauma, prior lung disease, history of lung cancer,
and smoking history were examined utilizing t-test and
statistical significance was assumed if P<0.05.
Results
One hundred and three [103] consecutive patients were
identified who received alteplase therapy for management
of loculated pleural fluid collections. The age of the patients
ranged from 20–91 y (mean 57.2 y); 68 (66%) were male.
The most common co-morbidity was hypertension (55%,
n=60), and 35% (n=32) of patients had a history of smoking.
Additionally, 8 (7.7%) of patients had a previous history of
lung cancer, and 7 (6.8%) had a history of lung surgery. Of
patients with loculated pleural fluid collections, 20 (18.2%)
had a history of recent trauma (Tables 1,2).
Eight-two patients (79.6%) had a loculated pleural fluid
collection secondary to an empyema, and 21 (20.4%) had
a retained hemothorax. Of the 21 patients with a retained
hemothorax, 16 were secondary to blunt trauma with rib
fractures as the most common injury in 14 of the 16 trauma
patients. Penetrating trauma and malignant hemothorax
accounted for the remainder of the retained hemothoraces.
A third of the patients with a retained hemothorax became
secondarily infected. Three of the 21 patients with retained
hemothoraces died, caused by empyema, aspiration
pneumonia, and massive hemothorax.
Ninety-six patients (93.2%) were treated with antibiotics;
7 patients were not treated with antibiotics, and all had a
diagnosis of a retained hemothorax. The most common
antibiotics used were vancomycin (n=64), piperacillin/
tazobactam (n=60), fluoroquinolones (n=58), and
cephalosporins (n=58); 86 patients were prescribed more
than one antibiotic (Table 3).
The average length of stay (LOS) from day of
admission to discharge for was 25.9 days (3–143 days).
The average number of days in the hospital for the
diagnosis of a hemothorax and empyema was 21.9 and
26.9 days respectively (Table 3). Forty patients (36.4%)
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Table 1 Patient characteristics

Table 2 Patient characteristics

Variables

n (%)

Total number of patients

Variables

103

N

Gender

Average age

Hemothorax (%)

Empyema (%)

Total (%)

21 (20.4)

82 (79.6)

103

53.9

58.1

57.2

16 (76.2)

4 (4.9)

20 (19.4)

Male

68 (66.0)

Trauma

Female

35 (34.0)

DM

4 (19.0)

24 (29.3)

28 (27.2)

COPD

3 (14.3)

12 (14.6)

15 (14.6)

Tobacco use

7 (33.3)

37 (45.1)

44 (42.7)

12 (57.1)

48 (58.5)

60 (58.3)

Age (years)
Range

20–91

Mean

57.2

Median

HTN

56

Comorbidities (yes/no)
Diabetes

26 (25.5)/76 (74.5)

Hypertension

56 (54.9)/46 (45.1)

Lung disease

25 (24.5)/77 (75.5)

COPD

15 (14.7)/87 (85.3)

Asthma

12 (11.8)/90 (88.2)

Smoking

43 (41.7)/60 (58.3)

Trauma

20 (19.4)/83 (80.6)

Hemothorax

23 (22.8)/78 (77.2)

Effusion

101 (98.1)/2 (1.9)

Empyema

81 (83.5)/16 (16.5)

Table 3 Treatment for effusion
Variables
Number of patients with effusion

n=90
Chesttube
Tube Output
(ml)(mL)
MeanMean
chest
output

n=60

n=38

400
400

300
300

n=12
n=3

200
200

100
100
n=9

0

0

Day 1 1
Day

Day 2 2
Day

Day 3 3
Day 44
Day
Day
Day of receiving TPA
Day of receiving TPA

Day 55
Day

Day 66
Day

Figure 1 Mean chest tube output after TPA.

had follow-up visits, with a mean time to follow of 12 days
(range, 2–28 days). For the 103 patients reviewed, there
were 110 hemothoraces with installment of alteplase
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Number of patients treated with antibiotics

600
600

500
500

n (%)

96 (93.2)

Vancomycin

64 (63.4)

Piperacillin/tazobactam

60 (59.4)

Fluroquinolone

58 (57.4)

Cephalosporin

58 (57.4)

via the chest tube. The average time from diagnosis to
alteplase treatment for a hemothorax was 12.8 days (range,
1–32 days); and 16.2 days (range, 4–48 days) for an
empyema. Patients with a history of lung disease had a
statistically significant shorter time from diagnosis to TPA
therapy; mean 9.4 days compared to 16.3 days for patients
without lung disease (P=0.009).
The mean number of days on alteplase therapy was
2.2±1.4 days, (range, 1–11 days). The average chest tube
output after day 1 was 509.8, after day 2 was 456.6 and
after day 3 was 445.8 (Figure 1). Eighty-seven (79.1%) had
their chest tube removed prior to discharge. The average
time from alteplase completion to chest tube removal was
5.7±4.5 days (range, 1–21 days). Eleven patients (10.7%)
underwent decortication; of which 5 had a retained
hemothorax and 6 had a loculated pleural effusion. After
completion of alteplase therapy, the average time to
discharge was 10.2 days (range, 1–109 days). The average
time from completion of alteplase therapy to discharge
in the hemothorax and empyema groups was 6.9 and
11.1 days, respectively (Table 4).
Seventeen patients (16.5%) died; 3 patients (14.3%) died
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Table 4 Hemothorax and empyema
Variables
N

Hemothorax

Empyema

Total

21

82

103

Surgery

5 (24%)

Mortality

3 (14.3%)

6 (7.3%)

11 (10.7%)

14 (17.1%)

17 (16.5%)

Total days in hospital
average

21.9

26.9

25.9

Time from TPA
completion to
discharge (days)

6.9

11.1

10.2

1

2

3

Complications

in the hemothorax group, while 14 patients (17.1%) died
in the empyema group. The cause of death was: sepsis (4),
respiratory failure (5), aortic injury causing hemorrhage (1),
cardiac arrest (1), aspiration (1), and progression of
malignancy (1). The patient who died of an aortic injury
presented as trauma patient with a massive left hemothorax
after a high speed motor vehicle collision. The patient
developed a retained hemothorax; TPA was administered
and the chest tube drained 2.5 liters of sanguineous fluid.
The patient was transferred to the intensive care unit. The
patient had a cardiac arrest in the intensive care unit and was
emergently taken to the operating room for an exploratory
left thoracotomy. Three liters of bright red blood and clots
was evacuated from the chest. The autopsy demonstrated an
undiagnosed aortic laceration secondary to rib fractures of
ribs 9 and 10. The hematoma was stable for 9 days and the
patient became unstable after the administration of TPA.
The TPA probably removed the clotted blood that had
caused a tamponade of the injury. He died in the operating
room.
Discussion and conclusions
Fibrinolytics have been used in the intrapleural space
as a means to break up the loculations that occur as the
physiological response to parapneumonic effusions and
allow re-expansion of the lung (1,2,6-9). Inflammation
and the presence of mesothelial cells in the pleural space
bring about the fibrinopurulent phase, where the effusion
becomes infected and there is an imbalance between
coagulation and fibrinolysis (5,6). Fibrinolysis is inhibited,
causing deposits to occur along the pleura, resulting in
loculations and an empyema (6).
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Fibrinolytics such as streptokinase and urokinase were
the first agents used to activate the fibrinolytic system and
activate plasminogen directly (3,5-7,10,11). These actions
allow for the dissolution of fibrin complexes present in
the parapneumonic effusion or empyema (6). TPA acts to
break up the fibrinous debris, allowing drainage of fluid (5).
The half-life of TPA in the blood is only 6 minutes and is
undetermined in the pleural space, therefore the appropriate
dwell, amount, and timing of TPA is still undetermined (6).
The efficacy of fibrinolytics in loculated pleural effusions
and empyemas has been questioned in the literature. A
double blind randomized study by Maskell and colleagues in
the New England Journal of Medicine found that intrapleural
administration of streptokinase does not improve mortality,
the rate of surgery, or the length of hospital stay (2,6). This
study randomized patients to placebo or control groups,
with control groups receiving 250,000 IU of streptokinase
diluted in 30 mL of normal saline delivered into the pleural
space every 12 hours for 6 doses total. There was a slightly
higher number of adverse events in the streptokinase group
in Maskell’s study, but this was not a statistically significant
difference (P=0.08) (2).
A Cochran review concluded that fibrinolytic therapy
showed benefit by reducing need for surgical intervention
despite the 2005 trial by Maskell (7). Stefanutti et al.
reported success with intrapleural instillation of urokinase
in pediatric patients using weight adjusted doses (8). Only
4 of 41 patients required further operative treatment for
parapneumonic effusions (8). Furthermore, Thommi and
colleagues found that alteplase was significantly more
effective than placebo in reducing surgical interventions
in patients with empyemas (1). In this study, 95 percent
of patients received adequate drainage and treatment,
compared to 12 percent in the placebo group (1).
Froudarakis and colleagues performed a prospective
study in twenty patients with intrapleural administration of
recombinant TPA for parapneumonic effusions or persistent
pleural effusions (5). They found a 95% success rate with
the use of intrapleural TPA, with improved drainage after
instillation, decrease in inflammatory mediators such as
white blood cells and CRP, and minimal complications (5).
Complications were described as mild pain with instillation
and mild, local hemorrhage in 3 of 20 patients (5).
A retrospective review of 118 patients found successful
treatment of parapneumonic and pleural effusions in 69.5
percent of patients treated with one to eight doses of 25 mg
of alteplase diluted in 120 mL of saline and instilled into
the intrapleural space. Intrapleural alteplase was successful
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in 78.1 percent of empyemas, 61.5 percent of patients with
hemothoraces, 100 percent of those with malignancy as a
cause of the pleural process, 71.4 percent of complex pleural
effusions, and 48 percent of parapneumonic effusions.
Success was determined by resolution or near resolution of
the fluid collection on imaging with avoidance of surgical
intervention. The overall effectiveness of alteplase was
86.4 percent, with the highest success rate noted after
one or two doses. Patients who required more than two
doses were more likely to have residual disease, suggesting
operative intervention should be considered after two doses.
Unsuccessful treatment occurred in 35 patients, seven of
these patients experienced bleeding requiring operative
intervention. Bleeding was associated with empyema in
6.3 percent, malignancy in 12.5 percent, complex pleural
effusion in 4.8 percent, and parapneumonic effusion in 8
percent (9). This comparatively high rate of bleeding may
result from higher dosing used in that study.
Rehman and colleagues (12) randomized patients to
receive placebo, TPA, DNase or TPA plus DNase. They
found no difference between placebo and TPA with respect
to avoiding surgical deloculation. When DNase was added
to TPA, only 4% were referred for surgical intervention
when followed over a three month period. A 1 hour dwell
time with 10 mg of TPA was used twice daily (12).
Surgical management remains an option in the
management of empyema and at one point was considered
the gold standard (13). Chen and colleagues reviewed
thoracoscopic management of 101 pediatric empyemas in
their institution (4). In their study the median duration of
time from diagnosis of empyema to surgical management
was 4 days, however, 35.6 percent first underwent
thoracostomy tube placement followed by thoracoscopic
management. The median duration of chest tube duration
was 6 days with a range between 1 and 28 days. Chen and
colleagues noted increased difficulty with surgery when a
chest tube was placed preoperatively, noted by statistically
significant increased operative time in the thoracostomy
tube group (94 versus 72 minutes). Primary treatment with
thoracoscopy was performed in 65 percent of patients. In
this study 32.7 percent were treated in the intensive care
unit preoperatively, which was associated with a prolonged
hospital stay. The median duration of hospital stay
postoperatively in this study was 13 days (4).
St Peter and colleagues performed one of the first
prospective studies comparing thoracoscopic and
intrapleural fibrinolytics in children (13). In this study 18
children were randomized to fibrinolysis versus surgical
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management. The results showed similar outcomes in
regards to post treatment LOS, days of oxygen support,
time to defervescence, and analgesia. A statistically
significant difference was found between the hospital
charges between the patient groups. The surgical group
averaged $11,700 in hospital charges versus $7,600 for
the fibrinolysis group. Only three patients (16.6 percent)
failed fibrinolytic therapy in this study, requiring surgical
thoracoscopy for definitive management. In the surgical
group, two of the patients became clinically worse,
requiring ventilator support, progression of sepsis, and
requiring temporary hemodialysis, while no progression of
disease occurred in the fibrinolytic group (13).
Sonnappa et al. had similar results in their prospective
randomized trial for children with empyema, comparing
thoracoscopic decortication compared to intrapleural
fibrinolysis with urokinase (10). There was no difference in
time to discharge after intervention between the fibrinolytic
and surgical group. Their surgical group were able to
remove the chest drain 1 day earlier than the fibrinolytic
group (P=0.055). Only 2 of the patients in the fibrinolytic
therapy group required thoracoscopic surgery for definitive
management. The surgical group had a 25 percent increase
in cost compared to the fibrinolytic therapy group, similar
to the findings of St Peter (10,11).
Surgical therapy is not without risks. In elderly patients
with multiple co-morbidities, mortality can be up to 5
percent in thoracoscopic surgery and 10 percent with
decortication. Recurrence of empyema can occur in up to
2.6 percent of patients treated surgically. Complications
can occur, including bleeding, infection, intolerance to
single lung ventilation, re-expansion pulmonary edema,
prolonged ventilation, intercostal neuralgia, air leaks,
and bronchopleural fistulas. Postoperative pain can cause
additional problems, especially in the elderly patients (1).
In our study, the average hospital stay was 25.9 days,
with the diagnosis of loculated pleural fluid collection or
empyema was diagnosed later in the hospital course. The
delay in treatment, was secondary to all of these patients
were referred and the thoracic surgery service was the
consulting service. As the treatment protocol was refined,
and conversations were had with the referring services, the
time to referral for treatment decreased. Only 10.7 percent
of these patients failed thrombolytic treatment, requiring
surgical decortication. This is inferior to the results of
Rehman et al. when DNase was added but far superior to
their results for TPA alone. They found that only 4% of
patients were referred for surgery. This was when patients
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were followed over three months. We referred no patients
for surgery after hospital discharge. They found no
difference from placebo when TPA was used alone. This
may have been related to their short dwell time, implying
that dwell time may be more important than higher doses,
10 mg, in this case, more frequent administration and
perhaps even the addition of DNase. Their results may
also have been adversely affected by their reliance on
changes in plain radiography to assess effectiveness. In our
experience, plain radiography is insufficiently sensitive
and can lead to confusion between residual effusion and
residual parenchymal consolidation. In our study, TPA
led to near complete resolution of the effusion when CT
was used to evaluate effectiveness. We also utilized a much
more truncated time schedule, referring patients for surgery
after failure at three days, rather than over a period of three
months.
Those patients with a known history of lung disease
had a statistically significant earlier time to diagnosis and
initiation of fibrinolytic therapy. Those patients may have
been monitored more closely because of their known
comorbidity. Overall, the data shows that a significant
number of patients with class 5–7 pleural effusions and
empyemas can a benefit from intrapleural fibrinolytic
therapy and that all such patients warrant a trial of
intrapleural thrombolytics prior to committing to surgical
intervention. This approach may reduce the cost and
morbidity.
The variability in outcomes of intrapleural fibrinolytics
in the literature can be attributed to inconsistent study
characteristics (6). For example, the criteria for the use of
fibrinolytics, dose, timing of the doses, variation of chest
tubes, and indications for surgery were not standardized
in many of the studies. In addition, patients who received
intrapleural fibrinolytics in many of the prior studies may
have been poor surgical candidates who would not have
survived a surgical treatment, such as thoracoscopic or open
thoracotomy approach.
We present the largest, consecutive series to date of
complex pleural effusions treated with alteplase. We
utilized a low dose with once daily administration that
did not result in any bleeding events. This was associated
with a very low proportion of patients requiring salvage
decortication. Fibrinolytic therapy has been associated
with lower hospital costs, decreased pain, and minimal
complications. Some patients may not respond to treatment
with fibrinolytic therapy, and at that point surgical therapy
may be appropriate for further treatment. Further studies
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are needed to determine the effect of dose, dwell time and
frequency of administration on outcomes.
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